All News

2018

May

Media Release / May 24, 2018

Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseases

Read More
Media Release / May 02, 2018

Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab

Read More

April

Media Release / Apr 19, 2018

Novartis delivered a strong first quarter and acted to become a more focused medicines company

Read More
Media Release / Apr 18, 2018

Sandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disorders

Read More
Media Release / Apr 07, 2018

Sandoz outlines plans for next Healthcare Access Challenge (HACk), to support local digital innovation

Read More

March

Media Release / Mar 23, 2018

Sandoz receives positive CHMP opinion for proposed biosimilar infliximab

Read More

February

Media Release / Feb 13, 2018

Sandoz announces US FDA approval and launch of Glatopa® 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis

Read More
Media Release / Feb 01, 2018

Sandoz certified as Top Employer Europe 2018

Read More

January

Media Release / Jan 24, 2018

Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase

Read More
Media Release / Jan 18, 2018

Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars

Read More

Pages